Research programme: 14-3-3 inhibitors - UniSA Ventures

Drug Profile

Research programme: 14-3-3 inhibitors - UniSA Ventures

Latest Information Update: 04 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of South Australia
  • Developer UniSA Ventures; University of South Australia
  • Class Small molecules
  • Mechanism of Action 14-3-3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Wounds
  • Research Cancer

Most Recent Events

  • 04 Aug 2016 Research programme: 14-3-3 inhibitors - UniSA Ventures is available for licensing -
  • 03 Aug 2016 Early research in Cancer in Australia (PO)
  • 03 Aug 2016 Preclinical trials in Wounds in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top